CSI enters public domain through Replidyne merger
This article was originally published in Clinica
Executive Summary
Privately-held medical device company Cardiovascular Systems Inc (CSI) is to make its debut on the Nasdaq via a stock-for-stock merger with Replidyne, a struggling, publicly-listed biotechnology firm.